AGTX Agentix Corp.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1603345 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY44.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-10,542.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets290,269.6%
Debt / equity—
Current ratio0.00x
Interest coverage-3.57x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-9,875.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $4,191 | $16,635 | $0 | $0 | $25,079 | $100,000 | $90,349 | $23,287 |
| SG&A expense | $16,785 | $16,785 | $16,785 | $16,785 | $16,785 | $17,717 | $17,348 | $16,896 |
| Operating income | -$68,169 | -$95,504 | -$54,285 | -$67,463 | -$123,097 | -$200,342 | -$172,121 | -$96,815 |
| Interest expense | $23,158 | $22,170 | $20,917 | $13,804 | $24,159 | $21,226 | $13,895 | $11,295 |
| Pretax income | -$91,025 | -$117,674 | -$77,110 | -$78,595 | -$144,107 | -$185,824 | -$181,768 | -$143,894 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$91,025 | -$117,674 | -$77,110 | -$78,595 | -$144,107 | -$185,824 | -$181,768 | -$143,894 |
| EPS (diluted) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Weighted avg. shares (diluted) | 40.07M | 40.07M | — | 40.07M | 40.07M | 40.07M | — | 40.07M |
| Balance sheet | ||||||||
| Cash & equivalents | $1,312 | $38 | $771 | $6,396 | $5,601 | $4,412 | $4,477 | $8,273 |
| Current assets | $1,312 | $38 | $771 | $6,396 | $5,601 | $4,412 | $100,274 | $154,111 |
| Total assets | $1,312 | $38 | $771 | $6,396 | $5,601 | $4,412 | $100,274 | $154,111 |
| Current liabilities | $3.81M | $3.71M | $3.60M | $3.50M | $3.42M | $3.28M | $3.20M | $3.07M |
| Total liabilities | $3.81M | $3.71M | $3.60M | $3.50M | $3.42M | $3.28M | $3.20M | $3.07M |
| Shareholders' equity | -$3.81M | -$3.71M | -$3.60M | -$3.50M | -$3.42M | -$3.27M | -$3.10M | -$2.92M |
| Shares outstanding | 40.07M | 40.07M | 40.07M | 40.07M | 40.07M | 40.07M | 40.07M | 40.07M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3,522 | -$26,372 | $14,776 | -$7,938 | $3,004 | -$118,371 | -$43,058 | -$86,999 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $7,000 | $26,250 | $0 | $10,100 | $350 | $100,000 | $45,000 | $25,000 |
Free plan shows the latest 8 periods; Pro shows all 56 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.